- Home
- ELVN vs COLL Comparison
ELVN vs COLL Comparison
Compare ELVN & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- COLL
- Stock Information
- Founded
- ELVN 2016
- COLL 2002
- Country
- ELVN United States
- COLL United States
- Employees
- ELVN N/A
- COLL N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- ELVN Health Care
- COLL Health Care
- Exchange
- ELVN Nasdaq
- COLL Nasdaq
- Market Cap
- ELVN 1.2B
- COLL 958.8M
- IPO Year
- ELVN 2020
- COLL 2015
- Fundamental
- Price
- ELVN $20.73
- COLL $30.35
- Analyst Decision
- ELVN Strong Buy
- COLL Strong Buy
- Analyst Count
- ELVN 5
- COLL 4
- Target Price
- ELVN $41.20
- COLL $43.75
- AVG Volume (30 Days)
- ELVN 747.2K
- COLL 289.9K
- Earning Date
- ELVN 08-12-2025
- COLL 08-07-2025
- Dividend Yield
- ELVN N/A
- COLL N/A
- EPS Growth
- ELVN N/A
- COLL N/A
- EPS
- ELVN N/A
- COLL 1.25
- Revenue
- ELVN N/A
- COLL $664,283,000.00
- Revenue This Year
- ELVN N/A
- COLL $20.04
- Revenue Next Year
- ELVN N/A
- COLL $3.98
- P/E Ratio
- ELVN N/A
- COLL $24.19
- Revenue Growth
- ELVN N/A
- COLL 17.17
- 52 Week Low
- ELVN $13.30
- COLL $23.23
- 52 Week High
- ELVN $30.03
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- ELVN 52.08
- COLL 54.25
- Support Level
- ELVN $19.22
- COLL $29.28
- Resistance Level
- ELVN $21.90
- COLL $30.83
- Average True Range (ATR)
- ELVN 1.49
- COLL 0.75
- MACD
- ELVN -0.19
- COLL -0.00
- Stochastic Oscillator
- ELVN 39.43
- COLL 51.63
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.